Page 5 - Nucleus Network News Today

Six million Aussies from today will be able to make a GP appointment for a COVID-19 vaccine. See if your area is on the list.

The PM is not concerned about Europe’s move to pause the AstraZeneca vaccine, as the final analysis for the Novavax jab on order in Australia was revealed.

Health by Sue Dunlevy, National Health Editor 12th Mar 2021 6:31 AM Premium Content   A COVID-19 vaccine pill that could revolutionise the control of the pandemic is being trialled in a handful of Australians. Not only would it eliminate the need for a painful jab, it could be stored at room temperature making it easy to transport and no medical workforce would be needed to deliver it. Australian clinical trial company Nucleus ...

The PM is not concerned about Europe’s move to pause the AstraZeneca vaccine, as the final analysis for the Novavax jab on order in Australia was revealed.

Recruiting for Phase 1 Clinical Trials During a Full Lockdown, Upcoming Webinar Hosted by Xtalks Share Article In this free webinar, the featured speakers will discuss how Nucleus Network pivoted from the familiar transient participant pool to a local population during a severe lockdown and how it was able to leverage the new profile of medical research and clinical trials to generate earned media coverage. Attendees will learn about strategies that were implemented to rapidly retarget to a new...

The early study results come amid worry about whether a vaccines being rolled out worldwide will be strong enough against new variants.

Tapeworm, vertigo and pancreatitis drugs are being trialled as COVID-19 treatments By the Specialist Reporting Teams Alison Branley and national medical reporter Sophie Scott Posted SunSunday 24 updated MonMonday 25 Australian researchers are part of global efforts to trial potential COVID-19 treatments. ( Print text only Cancel With COVID-19 vaccines on their way, its time to breathe a sigh of relief right? Well, maybe not. Key points: It includes drugs to treat tapeworm, pancreatitis, vertig...

Manufacturing and trial delays have meant Australia’s third vaccine has slipped off the radar – but early trial data raises hopes it could offer strong protection against and even halt the virus' spread.

COVID-19 swab in lab Photo: Getty Images A Burnaby biotech company is partnering with a global pharmaceutical giant on research into advancing delivery of oral vaccines, including for COVID-19. Symvivo Corporation, a clinical-stage biotechnology company that has a proprietary bacTRL gene delivery platform, announced Tuesday that it has entered into a research collaboration with Merck Sharp and Dohme Corp. Under the terms of the agreement, Merck receives an option to take an exclusive license to...